Satellos Bioscience (MSCL) Q3 2024 earnings summary

Executive summary

• Completed enrollment in first three of five single-ascending dose (SAD) cohorts for SAT-3247 in healthy volunteers, with no safety concerns reported.

• Initiated enrollment in the first multiple-ascending dose (MAD) cohort and completed the food effect dose cohort.

• Presented preclinical canine data showing SAT-3247 improved muscle strength to near normal levels.

• On track to complete SAD enrollment by year-end 2024, MAD by Q1 2025, and begin dosing DMD patients in Q4 2024.

Financial highlights

• Cash and cash equivalents of $23.4 million as of September 30, 2024, down from $39.6 million at December 31, 2023, due to operating activities.

• Net loss of $9.0 million ($0.08 per share) for Q3 2024, compared to $3.6 million ($0.03 per share) in Q3 2023.

• R&D expenses increased to $3.3 million in Q3 2024 from $2.7 million in Q3 2023, mainly due to clinical trial initiation and higher headcount.

• Recognized a non-cash impairment charge of $3.9 million to fully write down the remaining carrying value of an intangible asset.

• General and administrative expenses remained steady at $1.8 million year-over-year.

Outlook and guidance

• SAD cohort enrollment expected to complete by year-end 2024; MAD cohort by Q1 2025.

• Phase 1a adult DMD patient dosing planned for Q4 2024.

• Continued focus on advancing SAT-3247 as a disease-modifying treatment for DMD.